Mesoblast shares (ASX:MSB) fell sharply today, as markets continue to work through its preliminary first-quarter results. The Mesoblast share price closed out the opening trading session of the week down 11.06% at A$1.77, their lowest closing price in more than a year and just three cents above the stock’s 52-week low.
It has already been a painful year for holders, with shares now down 36.1% since the start of 2026, with today’s action putting MSB firmly at the bottom of the ASX 200 leaderboard for the day.
Latest Financials
Mesoblast reported Q1 FY26 net revenue from Ryoncil sales of US$28 million, a 44% increase on the US$19 million recorded in the prior corresponding period. While the year-over-year trajectory is clearly positive, the figure landed well below broker forecasts. Bell Potter, for instance, had pencilled in US$40 million for the quarter, a gap of roughly 30% that prompted the firm to trim its near-term revenue assumptions for FY27 by approximately 18%, cutting its forecast from US$243 million to US$203 million.
Management attributed the softer quarterly result to expected seasonal headwinds across July and August, a pattern common in hospital-based treatment settings during the northern hemisphere summer. The company noted that new patient starts rebounded to record levels in September, suggesting the underlying demand trajectory remains intact heading into Q2 FY26.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
On the operational side, the results contained genuinely encouraging data points. Net operating cash spend fell 85% to just US$2.3 million, compared with US$14.9 million in Q1 FY25 — a dramatic improvement that reflects the company’s shift toward disciplined capital management as Ryoncil moves deeper into commercial maturity. Mesoblast ended the September quarter with a cash balance of US$99 million, providing a meaningful runway as the company funds both its commercial manufacturing operations and a pipeline of late-stage clinical programs. All reported results are preliminary and subject to audit.
Ryoncil remains the first and only FDA-approved mesenchymal stromal cell therapy for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGVHD), a rare and life-threatening condition with limited treatment alternatives. The therapy is now available across 54 onboarded treatment sites, and Mesoblast continues to work toward expanding hospital penetration both domestically in the United States and through commercial partnerships internationally.
On the regulatory front, the US FDA approved Mesoblast’s implementation of a new T-cell Proliferation Inhibition BioAssay (TIBA) potency assay for commercial batch release and stability monitoring in late September 2026. The approval is a meaningful operational milestone, as it clears a potential manufacturing bottleneck that could have constrained the company’s ability to scale production for broader site expansion and future label extensions.
What Next?
Bell Potter maintained its Buy rating on Mesoblast following the quarterly update, trimming its price target to A$4.40 while reaffirming its long-term thesis. The broker’s position reflects a view that the Q1 revenue miss was driven by temporary seasonal factors rather than any structural deterioration in demand for Ryoncil. At A$4.40, Bell Potter’s target implies more than 148% upside from Monday’s close, a gap that illustrates just how wide the divergence has grown between current market pricing and the broker’s base-case valuation.
Looking further ahead, progress on international commercial partnerships in Europe and Asia, alongside regulatory updates on adult SR-aGVHD and pipeline programs, will be closely watched. Mesoblast enters the final quarter of calendar 26 with a strengthening operational foundation and a cash position that affords it time to execute, but Monday’s sell-off makes clear that markets want to see momentum converted into hard quarterly numbers.
Bull Case:
- Ryoncil revenue grew 44% year-over-year, confirming a clear commercial growth trend.
- Cash burn fell 85%, dramatically reducing near-term dilution and capital raise risk.
- US$99 million cash balance provides strong runway for pipeline and commercial expansion.
- Record September patient starts suggest seasonal Q1 weakness was temporary.
- FDA TIBA assay approval removes a key manufacturing bottleneck for scaling production.
Bear Case:
- Q1 revenue of US$28 million missed Bell Potter’s US$40 million forecast by 30%.
- FY27 broker revenue forecasts cut 18%, signalling eroded near-term earnings confidence.
- Shares down 36.1% year-to-date, reflecting persistent execution concerns versus expectations.
- Sustained cash-flow positivity remains unproven without consistent quarterly revenue acceleration.
- Ryoncil’s narrow paediatric label limits addressable market until adult trial data emerges.
